Estrella Immunopharma, Inc. (ESLA)
$
1.23
-0.07 (-5.69%)
Key metrics
Financial statements
Free cash flow per share
-0.0675
Market cap
51.7 Million
Price to sales ratio
0
Debt to equity
-0.0004
Current ratio
0.1515
Income quality
0.1855
Average inventory
0
ROE
3.0651
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Estrella Immunopharma, Inc. is a preclinical-stage biopharmaceutical company focused on developing T-cell therapies for blood cancers and solid tumors in the United States. The company reported an income before tax of -$8,845,941.00 showcasing its pre-tax profitability. With a gross profit standing at $0.00 the company highlights its profitability from core operations. The total costs and expenses for the company are $8,845,941.00 reflecting its overall spending strategies in research and development. Furthermore, the net income ratio is 0.00 indicating the company's profitability margin, while the earnings per share (EPS) is reported at -$0.25 marking the company's profitability on a per-share basis. The lead product candidates developed by Estrella include EB103, aimed at treating diffuse large B-cell lymphoma, which is currently in preclinical trials, and EB104, targeting diffuse large B-cell lymphoma and acute lymphocytic leukemia. The company has also established a collaborative partnership with Imugene Limited to develop solid tumor treatments utilizing Imugene's product candidate CF33-CD19t alongside EB103. Estrella Immunopharma, Inc. is based in Emeryville, California, and aims to make significant contributions to oncology. In terms of market positioning, the stock is affordable at $1.11 making it suitable for budget-conscious investors. However, the stock has a low average trading volume of 225,816.00 indicating lower market activity. With a market capitalization of $51,702,066.00 the company is classified as a small-cap player, demonstrating its emerging presence in the market. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape, and it belongs to the Healthcare sector, driving innovation and growth. Through its strategic initiatives and focused product development, Estrella Immunopharma, Inc. seeks to play a vital role in advancing healthcare solutions.
Is Estrella Immunopharma, Inc. (ESLA) a good investment?
Investing in Estrella Immunopharma, Inc. (ESLA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Estrella Immunopharma, Inc. (ESLA)'s stock forecast?
Analysts predict Estrella Immunopharma, Inc. stock to fluctuate between $0.73 (low) and $3.15 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Estrella Immunopharma, Inc.'s market capitalization?
As of 2026-02-13, Estrella Immunopharma, Inc.'s market cap is $51,702,066, based on 42,034,200 outstanding shares.
How does Estrella Immunopharma, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Estrella Immunopharma, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Estrella Immunopharma, Inc. (ESLA) stock?
To buy Estrella Immunopharma, Inc. (ESLA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ESLA. Place an order (Market, Limit, etc.).
What is the best time to invest in Estrella Immunopharma, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Estrella Immunopharma, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$0.25 | Growth: 19.05%.
Where can I find Estrella Immunopharma, Inc.'s investor relations reports?
Visit https://www.estrellabio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Estrella Immunopharma, Inc.?
You can explore historical data from here
What is the all-time high and low for Estrella Immunopharma, Inc. stock?
All-time high: $5.62 (2023-10-02) | All-time low: $0.63 (2024-10-31).
What are the key trends affecting Estrella Immunopharma, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
5 days ago
EMERYVILLE, Calif.--(BUSINESS WIRE)-- #2026TandemMeetings--Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT & CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood & Marrow Transplant Research). The oral prese.
businesswire.com
11 days ago
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (Nasdaq: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced its STARLIGHT-1 phase I result will be orally presented at the 2026 ASTCT & CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood & Marrow Transplant Researc.
businesswire.com
a month ago
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases, today announced the closing of its previously announced registered direct offering, with a single healthcare-focused institutional investor, for the issuance and sale of 4,063,290 shares of the Company's common stock and 1,000,000 pre-funded warrants.
businesswire.com
a month ago
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases, today announced that it has entered into definitive agreements with a single healthcare-focused institutional investor for the purchase and sale of shares of common stock, par value $0.0001 per share (“Common Stock”) and pre-funded warrants (the “Pre-Funded.
defenseworld.net
2 months ago
Foghorn Therapeutics (NASDAQ: FHTX - Get Free Report) and Estrella Immunopharma (NASDAQ: ESLA - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations. Profitability This table compares Foghorn Therapeutics and
businesswire.com
2 months ago
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that an independent Data Safety Monitoring Board (DSMB) has completed its review of safety data from the Phase I dose escalation portion of the STARLIGHT-1 trial. Based on the favorable safety profile observed, the DSMB recommen.
businesswire.com
3 months ago
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the successful completion of the second dose cohort in Phase I portion of its STARLIGHT-1 Phase I/II clinical trial of EB103, a CD19-redirected ARTEMIS® T-cell therapy to treat patients with Advanced B-Cell Non-Hodgkin's Lymphom.
businesswire.com
4 months ago
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, announces that, as previously disclosed in its Current Report on Form 8-K filed on September 29, 2025, the Company has regained compliance with the listing requirements of The Nasdaq Stock Market LLC (“Nasdaq”). This confirmation follows the Co.
businesswire.com
9 months ago
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been dosed in the second cohort of its dose escalation study of Phase I/II STARLIGHT-1 trial for EB103, a CD19-redirected ARTEMIS® T-cell therapy to treat patients with Advanced B-Cell Non-Hodgkin's Ly.
businesswire.com
a year ago
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that CB Capital Partners has initiated coverage on the Company with a Buy rating and a price target of $14.00. “We appreciate CB Capital's detailed evaluation of our proprietary ARTEMIS® T-cell platform and the progress we have.
See all news
